

Helicobacter pylori: A Clinical Review

Jamil Ahmad Lakhari¹, Muhammad Arif Khan², Ali Akash³, Muhammad Imran^{4*}, Muhammad Hashim Raza⁵

1. Combined Military Hospital, Quetta, Baluchistan, Pakistan
2. Assistant Director, Medical Services, GHQ, Rawalpindi, Punjab, Pakistan
3. Department of ENT, CMH, Multan, Punjab, Pakistan
4. Department of Accidents and Emergency, DHQ Hospital, Layyah, Punjab, Pakistan
5. Department of Pathology, DHQ Hospital, Layyah, Punjab, Pakistan

* E-mail of the corresponding author: imranmerani247@gmail.com

Abstract

Helicobacter pylori, a gram negative microorganism, concomitant with a ramification of gastro-intestinal illnesses blanketed duodenal, non-ulcer dyspepsia, and gastric ulcer and active persistent gastritis. The frequency of *H. pylori* contamination ought to more than ninety % in patients showing sign and symptoms of gastrointestinal infections. It has been reported of affiliation of *H. pylori* infection with complication of stomach cancer. It may be transmitted through oro-fecal rely via the eating of waste-polluted water or meals. Combination of antibiotics and bismuth compounds found to be powerful in treating lively infection. Diagnosis of infection is through invasive testing techniques i.e. histology, Culture, based totally on endoscopy and biopsy, or non-invasive trying out strategies, which include serologic antibody assay, urea breath test and stool antigen test. Serologic antibody assay and UBT do no longer distinguish between a current infection and past cured infection. The stool antigen test is used to detect antigen presence inside the faeces that suggests lively infection. It can be extensively utilized to monitor the prognosis of disease and the recurrence. Prevention is by means of hygiene measures like hand washing practice and transmission control. If infection left untreated may also lead to critical hassle.

Keywords: *H. Pylori*, *Helicobacter Pylori*, Clinical Review

1. Introduction

Helicobacter pylori is gram-negative and micro-aerophilic bacterium. It typically found in the stomach. Two Australian scientists naming Barry Marshall and Robin Warren identified *H. Pylori* during investigation of person suffering with gastric ulcers and chronic gastritis, in 1982. It is also associated to the occurrence of duodenal ulcers and may lead to stomach cancer. About eighty % of persons are asymptomatic, infected with the bacterium (Blaser 2006). Even with the reducing incidence of *H. pylori* infection, this bacteria still infects thirty to fifty % of the populace in European countries (Zagari, Romano et al. 2015). *Helicobacter pylori* is a small, curved rod-shaped bacterium. It is believed that transmission to be mainly via fecal-oral route. It is estimated that about two-thirds of the world's population is infected, but it is more prevalent in developing countries ("*Helicobacter pylori*", 2018).

3. Epidemiology:

It is reported that half of the world's population is infected by the bacterium, making it the most pervasive infection over the world (Pounder and Ng 1995). Infections are typically attained in early childhood (Kusters, van Vliet et al. 2006). The infection rate in children of underdeveloped countries is higher as compared industrialized countries. It may be due to unnecessary usage of lower antibiotics for unrelated diseases, combined with deprived sanitary conditions. In developed countries, it is presently surprising to find infected children, but the percentage of infected people upsurges with age. With about fifty % infected for those over the age of 60 as compared to about ten % between eighteen and thirty years (Pounder and Ng 1995). The frequency seems higher in African-American and Hispanic populaces, may be due to socioeconomic elements in United states (Smoak, Kelley et al. 1994; Everhart, Kruszon-Moran et al. 2000).

4. Transmission:

H. pylori is communicable, though the meticulous route of transmission is not known (Megraud 1995; Cave 1996). It is accepted that person-person transmission by either the oral-oral or faeco-oral route. Transmission

happens primarily within families in developed countries, yet can also be assimilated from the community in developing countries (Delpont and van der Merwe 2007). *H. pylori* may likewise be transmitted through the ingestion of faecal polluted water, so a clean domain could help diminish the danger of *H. pylori* contamination (Brown 2000).

5. Clinical Manifestation:

It causes peptic ulcer illness. The most widely recognized ulcer indication is biting or consuming irritation in the epigastrium. This irritation commonly happens when the stomach is unfilled, amongst dinners and in the early morning hours; however, it can likewise happen at different circumstances. It might last from minutes to hours and might be soothed by eating or by taking stomach settling agents. Less basic ulcer indications incorporate queasiness, heaving, and loss of hunger. Draining can likewise happen; delayed draining may cause iron deficiency prompting shortcoming and weariness. In the case of draining is overwhelming, hematemesis, hematochezia, or melena may happen (CDC 2018).

6. Diagnosis:

There are two types of method which are invasive methods and non-invasive methods. Invasive methods include endoscopy, culture, rapid urease test, histology and molecular methods. There is advance in endoscopy strategies. While it isn't yet conceivable to recognize *Helicobacter pylori* specifically in the stomach, it ends up less demanding to distinguish the mucosal changes incited by the microscopic organisms. Some little changes can likewise build the affectability of the obtrusive tests, for instance culture or histology, yet the wide utilization of proton-pump inhibitors negatively affects these tests. Just atomic techniques can recognize a constrained heap of microscopic organisms, particularly by utilizing continuous PCR yet additionally with new strategies, for instance double preparing oligonucleotide-based PCR, circle sedated isothermal enhancement, bead computerized PCR or a different hereditary investigation framework ("Diagnostic of *Helicobacter pylori* infection", 2018).

While non-invasive methods incorporate urea breath test, stool antigen test and serology. Among the non-invasive tests, urea breath test remains a trial of significant intrigue, while there are endeavours to build up an ammonia breath test and other nanosensor gadgets. Another antigen stool test, a chemoluminescence immunoassay (CMIA) utilizing the LIAISON device has likewise been tried out of the blue with progress. In spite of its impediments, serology remains the most prominent test to recognize *H. pylori* antibodies. It likewise permits pepsinogen dose which is of enthusiasm for distinguishing decay ("Diagnostic of *Helicobacter pylori* infection", 2018).

Histologic identification of microorganisms deliberated the gold standard of analytical tests for *H. Pylori* (CDC 2018).

7. Treatment:

To enhance the management of contagion, doctor should consider following basic rules which are:

- (i) Probing former antibiotics use by patient
- (ii) Proton pump inhibitors high dose
- (iii) If it has unsuccessful already, not to repeat the same regimen (Zagari, Rabitti et al. 2018)

A general control in the experimental treatment of any irresistible sicknesses is to abstain from rehashing a similar anti-microbial regimen that is as of now fizzled. In the management of *H. pylori* disease, the disappointment of clarithromycin comprising triple treatment is normally identified with *H. pylori* essential or procured protection from clarithromycin (Farup, Lange et al. 2002). A study reported a very low abolition rate of 46% after reiterating a clarithromycin-containing remedy (Marin, McNicholl et al. 2013). Reiterating the same antimicrobial management of *H. pylori* infection should be sidestepped (Malfertheiner, Megraud et al. 2012; Fallone, Chiba et al. 2016; Chey, Leontiadis et al. 2017). In first line remedy numerous regimes have been recommended over the last few decades as first line management of *H. pylori*. The most corporate regimes are the clarithromycin comprising triple remedy stretched up to seven days and the bismuth quadruple and non-bismuth (sequential and concomitant) remedies (Marin, McNicholl et al. 2013). After the let-down of an empirical first-line treatment, doctors may use a levofloxacin triple remedy (PPI + levofloxacin + amoxicillin) or a bismuth quadruple therapy (Malfertheiner, Megraud et al. 2012; Fallone, Chiba et al. 2016; Chey, Leontiadis et al. 2017).

If second line treatment is not working to cure the infection, culture sensitivity testing is recommended to assess resistance. Third-line regimen should be prescribed later (Malfertheiner, Megraud et al. 2012; Fallone, Chiba et

al. 2016; Chey, Leontiadis et al. 2017). However, culture sensitivity testing for *H. Pylori* is not commonly accessible (Chey, Leontiadis et al. 2017). The real issue in clinical practice has been recognized by International guidelines finally recognized which provided recommendations for a realistic third-line cure. Recommendation is to use levofloxacin triple therapy, clarithromycin comprising therapies and bismuth quadruple therapy in third-line treatment if these were not used in first and second-line therapies (Malfertheiner, Megraud et al. 2012). As substitute for third and fourth-line treatments bismuth based levofloxacin quadruple therapy and a rifabutin containing triple therapy which is as amoxicillin + PPI + rifabutin, may be effective (Malfertheiner, Megraud et al. 2012; Fallone, Chiba et al. 2016; Chey, Leontiadis et al. 2017; Gisbert and Calvet 2012).

Table no. 1: Abolition therapy of *H. pylori* infection

First line	Second line	Third line
Bismuth quadruple/concomitant or two weeks clarithromycin	Amoxicillin triple + Levofloxacin + PPI	Prescribed on base of culture sensitivity report

7. Complications:

It frequently a few patients with *H. pylori* disease encounter no indications, while others may create genuine intricacies, including stomach ulcers and irritation of the stomach lining. Gastric tumour is the most extreme outcome of a *H. pylori* disease. Gastric MALToma, a type of lymphoma, might be treated with *H. pylori* destruction treatment and has a superior forecast than gastric disease. *H. pylori* disease is additionally connected with oesophageal growth, and may assume a part in a state of low blood platelets (idiopathic thrombocytopenic purpura).

8. Prevention and recommendation:

H. pylori microscopic organisms are available in sullied sustenance and water. In this way, it is critical to maintain a strategic distance from these sources (e.g., floodwater, crude sewage). It is prescribed to wash the hands completely with warm lathery water subsequent to utilizing the bathroom and before eating likewise may help forestall contamination. Eating utensils and drinking glasses ought to never be shared, since the microorganisms can be spread through spit.

9. Conclusion

H. pylori infection is still extremely prevailing infectious disease, and abolition remedy should be presented to all infected subjects. Diagnosis is important and if diagnosed positive than proper medication is required to eliminate infection. Awareness of infection transmission is key of prevention of disease. Hygiene care is also necessary. Suggested future works include developing a software package to facilitate the WOZIP data input and conversion processes, exploring the use of WOZIP in the other forms of labour-intensive manufacturing (e.g. flow-line production and work-cell assembly), and attaching a costing framework to determine the specific cost of each resource or to help minimise the aggregate cost of production.

References

- Blaser, M. J. (2006). "Who are we?: Indigenous microbes and the ecology of human diseases." *EMBO reports* 7(10): 956-960.
- Brown, L. M. (2000). "Helicobacter pylori: epidemiology and routes of transmission." *Epidemiologic reviews* 22(2): 283-297.
- Cave, D. R. (1996). "Transmission and epidemiology of Helicobacter pylori." *The American journal of medicine* 100: 12S-18S.
- CDC 2018. Retrieved from <https://www.cdc.gov/ulcer/files/hpfacts.pdf>
- Chey, W. D., G. I. Leontiadis, et al. (2017). "ACG clinical guideline: treatment of Helicobacter pylori infection." *The American journal of gastroenterology* 112(2): 212.
- Delport, W. and S. W. van der Merwe (2007). "The transmission of Helicobacter pylori: the effects of analysis method and study population on inference." *Best practice & research Clinical gastroenterology* 21(2): 215-236.
- Diagnostic of Helicobacter pylori infection. (2018). Retrieved from <https://onlinelibrary.wiley.com/doi/pdf/10.1111/hel.12333>

- Everhart, J. E., D. Kruszon-Moran, et al. (2000). "Seroprevalence and ethnic differences in *Helicobacter pylori* infection among adults in the United States." *The Journal of infectious diseases* 181(4): 1359-1363.
- Fallone, C. A., N. Chiba, et al. (2016). "The Toronto consensus for the treatment of *Helicobacter pylori* infection in adults." *Gastroenterology* 151(1): 51-69. e14.
- Farup, P. G., O. J. Lange, et al. (2002). "The effect of *Helicobacter pylori* retreatment with ranitidine bismuth citrate, clarithromycin, and metronidazole depends on the first-line therapy." *Journal of clinical gastroenterology* 35(5): 379-382.
- Gisbert, J. and X. Calvet (2012). "rifabutin in the treatment of refractory *Helicobacter pylori* infection." *Alimentary pharmacology & therapeutics* 35(2): 209-221.
- Helicobacter pylori*. (2018). Retrieved from <http://www.nc.cdc.gov>
- Kusters, J., A. van Vliet, et al. (2006). "Pathogenesis of *Helicobacter pylori* Infection *Clin Microbiol Rev* 19: 449-490." Crossref Google Scholar.
- Malferteiner, P., F. Megraud, et al. (2012). "Management of *Helicobacter pylori* infection—the Maastricht IV/Florence consensus report." *Gut* 61(5): 646-664.
- Marin, A. C., A. G. McNicholl, et al. (2013). "A review of rescue regimens after clarithromycin-containing triple therapy failure (for *Helicobacter pylori* eradication)." *Expert opinion on pharmacotherapy* 14(7): 843-861.
- Megraud, F. (1995). "Transmission of *Helicobacter pylori*: faecal-oral versus oral-oral route." *Alimentary pharmacology & therapeutics* 9: 85-91.
- Pounder, R. and D. Ng (1995). "The prevalence of *Helicobacter pylori* infection in different countries." *Alimentary pharmacology & therapeutics* 9: 33-39.
- Smoak, B. L., P. W. Kelley, et al. (1994). "Seroprevalence of *Helicobacter pylori* infections in a cohort of US Army recruits." *American journal of epidemiology* 139(5): 513-519.
- Zagari, R. M., M. Romano, et al. (2015). "Guidelines for the management of *Helicobacter pylori* infection in Italy: the III Working Group Consensus Report 2015." *Digestive and Liver Disease* 47(11): 903-912.
- Zagari, R. M., S. Rabitti, et al. (2018). "Treatment of *Helicobacter pylori* infection: A clinical practice update." *European journal of clinical investigation* 48(1): e12857.